Los Angeles Capital Management
NTLA icon

Los Angeles Capital Management’s Intellia Therapeutics NTLA Stock Holding History

Los Angeles Capital Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.91K Sell
617
-835
-58% -$10.6K ﹤0.01% 2000
2025
Q4 		$17.8K Buy
+1,452
New +$20K ﹤0.01% 1906
2024
Q3 		– Sell
-10,467
Closed -$234K – 1258
2024
Q2 		$234K Sell
10,467
-6,982
-40% -$166K ﹤0.01% 1091
2024
Q1 		$480K Buy
17,449
+5,754
+49% +$160K ﹤0.01% 881
2023
Q4 		$357K Buy
11,695
+422
+4% +$12.1K ﹤0.01% 962
2023
Q3 		$356K Buy
11,273
+294
+3% +$11.4K ﹤0.01% 915
2023
Q2 		$448K Buy
10,979
+1,078
+11% +$43.7K ﹤0.01% 886
2023
Q1 		$369K Sell
9,901
-762
-7% -$29.9K ﹤0.01% 950
2022
Q4 		$372K Sell
10,663
-1,280
-11% -$60.9K ﹤0.01% 975
2022
Q3 		$668K Buy
11,943
+1,301
+12% +$80.7K ﹤0.01% 833
2022
Q2 		$551K Buy
10,642
+767
+8% +$38.9K ﹤0.01% 934
2022
Q1 		$718K Sell
9,875
-1,050
-10% -$89K ﹤0.01% 892
2021
Q4 		$1.29M Sell
10,925
-101
-0.9% -$12.7K ﹤0.01% 634
2021
Q3 		$1.48M Buy
11,026
+1,106
+11% +$167K 0.01% 609
2021
Q2 		$1.61M Sell
9,920
-600
-6% -$46.7K 0.01% 648
2021
Q1 		$844K Sell
10,520
-16,025
-60% -$1.08M ﹤0.01% 973
2020
Q4 		$1.44M Sell
26,545
-600
-2% -$21.8K 0.01% 781
2020
Q3 		$540K Buy
27,145
+225
+0.8% +$4.69K ﹤0.01% 1048
2020
Q2 		$566K Sell
26,920
-350
-1% -$5.95K ﹤0.01% 1064
2020
Q1 		$334K Buy
+27,270
New +$367K ﹤0.01% 1022

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Los Angeles Capital Management's NTLA Position: Q1 2026 in Review

Los Angeles Capital Management reduced its Intellia Therapeutics (NTLA) stake by 58% in Q1 2026, selling an estimated $10.6K and leaving 617 shares worth $7.91K. The position accounts for ﹤0.01% of the portfolio, ranked #2000.

Los Angeles Capital Management first reported a position in NTLA in Q1 2020 and has held it in 20 quarters since. The position peaked at $1.61M in Q2 2021. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Los Angeles Capital Management held 617 shares of Intellia Therapeutics worth $7.91K as of Q1 2026.
  • Los Angeles Capital Management sold 835 Intellia Therapeutics shares in Q1 2026, an estimated $10.6K.
  • Intellia Therapeutics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #2000 holding.
  • Los Angeles Capital Management first reported a position in Intellia Therapeutics in Q1 2020 and has held it in 20 quarters since.
  • Los Angeles Capital Management's Intellia Therapeutics position peaked at $1.61M in Q2 2021.
  • 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.